Citi analyst Samantha Semenkow raised the firm’s price target on Immunovant to $51 from $50 and keeps a Buy rating on the shares post the fiscal Q2 earnings erport.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMVT:
- Immunovant files automatic mixed securities shelf
- Immunovant reports Q2 EPS (45c), consensus (47c)
- Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023
- IMVT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Immunovant management to meet virtually with Piper Sandler